Literature DB >> 10389696

Vascular endothelial growth factor (VEGF) in Crohn's disease: increased production by peripheral blood mononuclear cells and decreased VEGF165 labeling of peripheral CD14+ monocytes.

T Griga1, S Werner, M Köller, A Tromm, B May.   

Abstract

Recently, increased serum levels of vascular endothelial growth factor (VEGF) have been shown in patients with inflammatory bowel disease. The origins of the circulating VEGF are still not described. Monocytes play an important role in the inflammatory process. VEGF binding to monocytes mediates monocyte recruitment and activation. The present study investigates the VEGF production of peripheral blood mononuclear cells and the ability of peripheral monocytes to bind VEGF165 in patients with Crohn's disease. Nineteen patients with Crohn's disease and 10 healthy volunteers were studied. VEGF165 labeling of CD14+ monocytes was measured using two-color flow cytometry. Density of VEGF labeling was expressed as the mean fluorescence intensity (MFI). Furthermore, VEGF levels were determined in culture supernatants of unstimulated peripheral blood mononuclear cells. VEGF in culture supernatants was measured using a solid-phase enzyme-linked immunosorbent assay. There was a significantly decreased VEGF165 labeling of monocytes of patients with active Crohn's disease (MFI: 369.9+/-121.6, N = 7, P < 0.002) compared to patients with inactive disease (MFI: 457.7+/-74.5, N = 6) and healthy controls (MFI: 542.9+/-96.2, N = 10). Unstimulated peripheral blood mononuclear cells of patients with active Crohn's disease produced significantly higher amounts of VEGF (1142.6+/-483.9 pg/ml, N = 12, P < 0.001) compared with peripheral blood mononuclear cells of healthy volunteers (113.4+/-101.8 pg/ml, N = 10). VEGF production by peripheral blood mononuclear cells of patients with active disease was significantly increased compared to patients with quiescent disease (261.6+/-254.8 pg/ml, N = 7, P < 0.001). In conclusion, our data describe peripheral blood mononuclear cells as one of the origins of the elevated VEGF serum levels in patients with active Crohn's disease. Furthermore, a decrease in VEGF165 binding sites on peripheral monocytes of patients with active Crohn's disease has been shown. The study underlines the important role of VEGF in Crohn's disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10389696     DOI: 10.1023/a:1026640610621

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  25 in total

1.  The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis.

Authors:  M Clauss; H Weich; G Breier; U Knies; W Röckl; J Waltenberger; W Risau
Journal:  J Biol Chem       Date:  1996-07-26       Impact factor: 5.157

2.  High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis.

Authors:  B Millauer; S Wizigmann-Voos; H Schnürch; R Martinez; N P Møller; W Risau; A Ullrich
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

3.  Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes.

Authors:  H Shen; M Clauss; J Ryan; A M Schmidt; P Tijburg; L Borden; D Connolly; D Stern; J Kao
Journal:  Blood       Date:  1993-05-15       Impact factor: 22.113

4.  Expression of receptors for interleukin 4 and interleukin 7 on human T cells.

Authors:  R J Armitage; S F Ziegler; M P Beckmann; R L Idzerda; L S Park; W C Fanslow
Journal:  Adv Exp Med Biol       Date:  1991       Impact factor: 2.622

5.  Increased expression of interleukin-4 receptors on psoriatic epidermal cells.

Authors:  E Prens; J Hegmans; R C Lien; R Debets; R Troost; T van Joost; R Benner
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

6.  Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium.

Authors:  T P Quinn; K G Peters; C De Vries; N Ferrara; L T Williams
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

7.  A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF.

Authors:  L Seetharam; N Gotoh; Y Maru; G Neufeld; S Yamaguchi; M Shibuya
Journal:  Oncogene       Date:  1995-01-05       Impact factor: 9.867

8.  Expression of the flt3 receptor and its ligand on hematopoietic cells.

Authors:  K Brasel; S Escobar; R Anderberg; P de Vries; H J Gruss; S D Lyman
Journal:  Leukemia       Date:  1995-07       Impact factor: 11.528

9.  Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions.

Authors:  K T Yeo; H H Wang; J A Nagy; T M Sioussat; S R Ledbetter; A J Hoogewerf; Y Zhou; E M Masse; D R Senger; H F Dvorak
Journal:  Cancer Res       Date:  1993-06-15       Impact factor: 12.701

10.  Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration.

Authors:  M Clauss; M Gerlach; H Gerlach; J Brett; F Wang; P C Familletti; Y C Pan; J V Olander; D T Connolly; D Stern
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

View more
  6 in total

1.  VEGF₁₆₄ isoform specific regulation of T-cell-dependent experimental colitis in mice.

Authors:  John H Chidlow; John D Glawe; Christopher B Pattillo; Sibile Pardue; Songlin Zhang; Christopher G Kevil
Journal:  Inflamm Bowel Dis       Date:  2010-11-09       Impact factor: 5.325

2.  Elevated levels of vascular endothelial growth factor in serum of patients with D+ HUS.

Authors:  D Maroeska Te Loo; Nienke Bosma; Victor Van Hinsbergh; Paul Span; Rob De Waal; Ruud Clarijs; C Sweep; Leo Monnens; Lambertus Van Den Heuvel
Journal:  Pediatr Nephrol       Date:  2004-05-13       Impact factor: 3.714

3.  Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis.

Authors:  Janice A Nagy; Eliza Vasile; Dian Feng; Christian Sundberg; Lawrence F Brown; Michael J Detmar; Joel A Lawitts; Laura Benjamin; Xiaolian Tan; Eleanor J Manseau; Ann M Dvorak; Harold F Dvorak
Journal:  J Exp Med       Date:  2002-12-02       Impact factor: 14.307

4.  Characterization of Serum Cytokine Profile in Predominantly Colonic Inflammatory Bowel Disease to Delineate Ulcerative and Crohn's Colitides.

Authors:  Olga Y Korolkova; Jeremy N Myers; Samuel T Pellom; Li Wang; Amosy E M'Koma
Journal:  Clin Med Insights Gastroenterol       Date:  2015-05-06

5.  Up-regulation of intestinal vascular endothelial growth factor by Afa/Dr diffusely adhering Escherichia coli.

Authors:  Gaëlle Cane; Vanessa Liévin-Le Moal; Gilles Pagès; Alain L Servin; Paul Hofman; Valérie Vouret-Craviari
Journal:  PLoS One       Date:  2007-12-26       Impact factor: 3.240

6.  A zebrafish model of inflammatory lymphangiogenesis.

Authors:  Kazuhide S Okuda; June Pauline Misa; Stefan H Oehlers; Christopher J Hall; Felix Ellett; Sultan Alasmari; Graham J Lieschke; Kathryn E Crosier; Philip S Crosier; Jonathan W Astin
Journal:  Biol Open       Date:  2015-09-14       Impact factor: 2.422

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.